#cobenfy — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #cobenfy, aggregated by home.social.
-
Bristol Myers Squibb, an industry stalwart in need of a hit,
is betting a pill called #Cobenfy can become the first approved medicine for the millions of Americans diagnosed with psychosis related to Alzheimer’s disease.That case rests almost entirely on a single clinical trial, conducted before the DVD was invented,
in which its striking benefits were derailed by damning side effects.Later this year, Bristol will get the results from three pivotal studies designed to make good on the promise of that 30-year-old trial.
It’s the culmination of a scientific relay race, starting in the labs of Eli Lilly before ending up in the hands of a Boston startup called Karuna Therapeutics,
which came up with a clever way to rescue it from the pharmaceutical dustbin and nearly went out of business in the process.https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/
-
Bristol Myers Squibb has scored a significant victory with the FDA's approval of Cobenfy, a groundbreaking schizophrenia treatment! 🎉 This marks the first new type of schizophrenia drug in over 30 years, offering hope to millions. With its unique mechanism, Cobenfy aims to reduce symptoms without the common side effects of older medications. 💊✨ #MentalHealth #Schizophrenia #Cobenfy #FDAApproved #PharmaInnovation
-
Cobenfy (KarXT): A More Atypical Antipsychotic for Treatment of Schizophrenia
Cobenfy (also known as KarXT), a combination of the drugs xanomeline and trospium chloride, has been studied to be effective for the treatment of...........
#Antipsychotic #Cobenfy #FDA #KarXT #Schizophrenia
Neelesh Prasad -
One of the most satisfying aspects of covering biotech as long as I have
is the opportunity to report on the long arc of drug development, from start to finish.
It’s not always pretty, and more often than not, it ends badly.But #KarXT, now #Cobenfy, is one of those drug stories with a happy ending.
I remember talking to #Steven #Paul in 2019 for a story about the phase 2 results,
which were pretty remarkable.
Paul was excited about what KarXT might mean for people with #schizophrenia,
but he was cautious because, as he warned me at the time,
clinical trials for psychiatric conditions are extraordinarily difficult to replicate.
Let’s wait to see what KarXT does in Ph3 trials, he said.
Now, we know.It’s been cool to follow and report on the KarXT story all these years.
From PureTech to Karuna to Bristol Myers Squibb,
and now, to #approval, where Cobenfy will have a meaningful impact on people living with schizophrenia ...-- Adam Feuerstein
https://x.com/adamfeuerstein/status/1839623238525055101